LLY
Eli Lilly and Company
LLY has the edge over TARS overall, supported by stronger fundamentals and stronger modeled upside.
TARS
Tarsus Pharmaceuticals, Inc.
TARS's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TARS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
TARS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TARS PE Valuation
TARS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TARS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TARS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TARS on earnings quality, reporting a profit while its opponent remains loss making.
TARS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.16 | -$13.17 |
| Q2 2026 | -$1.06 | +$1.24 |
| Q1 2026 | -$1.11 | +$1.59 |
| Q4 2025 | -$1.59 | +$1.48 |
| Q3 2025 | -$1.99 | +$1.80 |
| Q2 2025 | -$2.30 | +$2.16 |
| Q1 2025 | -$2.70 | +$2.05 |
| Q4 2024 | -$3.07 | +$1.55 |
TARS lost $15.16 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TARS on profitability, with a higher operating margin.
TARS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $194.6M | +64% |
| Q2 2026 | $173.9M | +69% |
| Q1 2026 | $162.1M | +107% |
| Q4 2025 | $151.7M | +128% |
| Q3 2025 | $118.7M | +147% |
| Q2 2025 | $102.7M | +152% |
| Q1 2025 | $78.3M | +184% |
| Q4 2024 | $66.4M | +408% |
TARS has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -340% | -328 points |
| Q2 2026 | -11% | +10 points |
| Q1 2026 | -3.8% | +30 points |
| Q4 2025 | -5.3% | +32 points |
| Q3 2025 | -12% | +40 points |
| Q2 2025 | -22% | +60 points |
| Q1 2025 | -34% | +103 points |
| Q4 2024 | -37% | +303 points |
TARS's operating margin was −340% last quarter, down 328 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TARS on cash flow, with more consistent year-over-year improvement.
TARS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -144% |
| Q2 2026 | $57.2M | +$87.5M |
| Q1 2026 | -$30.5M | -$9.2M |
| Q4 2025 | $13M | +$35.2M |
| Q3 2025 | $16.3M | +$25.3M |
| Q2 2025 | -$30.4M | -$14.9M |
| Q1 2025 | -$21.2M | +$16.7M |
| Q4 2024 | -$22.3M | +$17.1M |
TARS's free cash flow has turned positive after six years mostly in the red: $32M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TARS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TARS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +3M shares |
| 1 year | +9% | +3.8M shares |
| 3 years | +52% | +15.8M shares |
| 5 years | +125% | +25.8M shares |
| Available history | +326% | +35.5M shares |
TARS has 46M diluted shares, up 9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | $1,000 |
| Q1 2020 | $27,000 |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TARS Net Leverage
TARS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TARS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 44.3 | Neutral |
TARS's weekly RSI is 56 (neutral) and its Stochastic is 44 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TARS PE vs Healthcare Sector
TARS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
TARS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 6.3% above |
| 20 week MA | $70.3 | 9.4% above |
| 50 week MA | $69.2 | 11% above |
| 100 week MA | $60.9 | 26% above |
| 200 week MA | $42.9 | 79% above |
TARS is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TARS on returns for 2026, with the stronger performance.
TARS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $44.0 | +114% |
| 2021 | $44.0 | $25.9 | -41% |
| 2022 | $25.9 | $14.5 | -44% |
| 2023 | $14.5 | $20.3 | +40% |
| 2024 | $20.3 | $55.0 | +172% |
| 2025 | $55.0 | $81.8 | +49% |
| 2026 YTD | $81.8 | $76.9 | -6% |
TARS's yearly returns have swung widely, from +172% in 2024 to −44% in 2022. It's down 6% so far in 2026.